We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The need for new antibiotics
- Decrease in number of new classes of antibiotics
- Why are so few antibiotics reaching the market?
- Companies leave the antibiotic research arena
- Targets
- Targeting bacterial molecules (genomics)
- Identifying a bacteria-specific essential gene
- Inhibition of essential gene product activity
- Kill of bacteria by inhibitor
- Problems with the genomic approach
- Bacteriophages
- Bacteriophage therapy
- Problems with bacteriophage therapy
- Targeting whole bacteria
- Multiplying bacteria as a target
- Non-culturable bacteria as a target
- Non-multiplying bacteria as a target
- Diseases with non-multiplying persistent bacteria
- Bacterial endocarditis
- Catheter infections (biofilms)
- Prosthesis infections (biofilms)
- Antibiotics and non-multiplying organisms
- Consequences of non-multiplying bacteria survival
- Methods for new antibiotics
- Helperby therapeutics
- Potential advantages of new antibiotics
- Non-multiplying bacteria - obstacles
- Many different subpopulations
- Fewer molecular targets
- Low penetration, high efflux
- High local concentration of bacteria
- Standardisation
- Minimum stationary-cidal concentration
- Minimum dormicidal concentration
- Conclusion
Topics Covered
- Urgent need for new antibiotics
- Why are so few antibiotics reaching the market
- Pharmaceutical companies leaving the research arena
- Targets
- Bacterial molecules (genomics)
- Problems with the genomic approach
- Bacteriophage
- Treatments and problems with bacteriophages
- Whole bacteria
- Conventional multiplying bacteria
- Non-culturable bacteria
- Non-multiplying bacteria
- Tuberculosis, bacterial endocarditis, catheter infections and prosthesis infections
- Ways of making new antibiotics against whole live bacteria
- Potential advantages and problems of making new antibiotics which kill non-multiplying and multiplying bacteria
- Standardization
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Coates, A. (2009, December 31). Overcoming resistance through novel drug targets [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 5, 2024, from https://doi.org/10.69645/MGBK1607.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Anthony Coates has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.